![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
, Pioglitazone
Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
Agonists of peroxisome proliferator-activated receptor (PPAR)-
have
been shown to reduce tumor necrosis factor-
(TNF-
)-induced
insulin resistance. On the other hand, sensitization of Kupffer cells to
lipopolysaccharide (LPS) and their production of TNF-
are critical for
progression of alcoholic liver injury. This study was intended to determine
whether pioglitazone, a PPAR-
agonist, could prevent alcohol-induced
liver injury. Rats were given ethanol (5 g/kg b.wt.) and pioglitazone (500
µg/kg) once every 24 h intragastrically. Ethanol for 8 weeks caused
pronounced steatosis, necrosis, and inflammation in the liver. These
pathological parameters were diminished greatly by pioglitazone. Kupffer cells
were sensitized to LPS after ethanol for 4 weeks as evidenced by aggravation
of liver pathology induced by LPS (5 mg/kg) and enhancement of LPS (100
ng/ml)-induced intracellular Ca2+ concentration
elevation in Kupffer cells. The parameters were diminished by treatment with
pioglitazone. LPS-induced TNF-
production by Kupffer cells from the
4-week ethanol group was 3 to 4 times higher than control. This increase was
blunted by 70% with pioglitazone. Gut permeability was 10-fold higher in the
4-week ethanol group, and pioglitazone treatment did not change the value.
Inclusion of TNF-
in culture media of Kupffer cells enhanced CD14
expression, LPS-induced intracellular Ca2+ concentration
response, and production of TNF-
. These results indicate that
pioglitazone prevents alcoholic liver injury through abrogation of Kupffer
cell sensitization to LPS.
Address correspondence to: Dr. Nobuhiro Sato, Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. E-mail: nsato{at}med.juntendo.ac.jp
This article has been cited by other articles:
![]() |
W. Shan, P. S. Palkar, I. A. Murray, E. I. McDevitt, M. J. Kennett, B. H. Kang, H. C. Isom, G. H. Perdew, F. J. Gonzalez, and J. M. Peters Ligand Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression Toxicol. Sci., October 1, 2008; 105(2): 418 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Ajmo, X. Liang, C. Q. Rogers, B. Pennock, and M. You Resveratrol alleviates alcoholic fatty liver in mice Am J Physiol Gastrointest Liver Physiol, October 1, 2008; 295(4): G833 - G842. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Miksa, R. Wu, X. Cui, W. Dong, P. Das, H. H. Simms, T. S. Ravikumar, and P. Wang Vasoactive Hormone Adrenomedullin and Its Binding Protein: Anti-Inflammatory Effects by Up-Regulating Peroxisome Proliferator-Activated Receptor-{gamma} J. Immunol., November 1, 2007; 179(9): 6263 - 6272. [Abstract] [Full Text] [PDF] |
||||
![]() |
I A Leclercq, C Sempoux, P Starkel, and Y Horsmans Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats Gut, July 1, 2006; 55(7): 1020 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Knight, B. B. Yeap, G. C. Yeoh, and J. K. Olynyk Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member {gamma}, but not {alpha} or {delta} Carcinogenesis, October 1, 2005; 26(10): 1782 - 1792. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Diehl, Z P Li, H Z Lin, and S Q Yang Cytokines and the pathogenesis of non-alcoholic steatohepatitis Gut, February 1, 2005; 54(2): 303 - 306. [Full Text] [PDF] |
||||